Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease

A.J. Palmer; L. Annemans; S. Roze; M. Lamotte; P. Lapuerta; R. Chen; S. Gabriel; P. Carita; R.A. Rodby; H.H. Parving; Dick de Zeeuw

doi:10.2337/diacare.27.8.1897

Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease

A.J. Palmer
, L. Annemans
, S. Roze
, M. Lamotte
, P. Lapuerta
, R. Chen
, S. Gabriel
, P. Carita
, R.A. Rodby
, H.H. Parving
, Dick de Zeeuw

Research output: Contribution to journal › Article › Academic › peer-review

83 Citations (Scopus)

Original language	Dutch
Pages (from-to)	1897 - 1903
Number of pages	7
Journal	Diabetes Care
Volume	27
Issue number	8
DOIs	https://doi.org/10.2337/diacare.27.8.1897
Publication status	Published - 2004

Keywords

URINARY ALBUMIN EXCRETION
MULTIFACTORIAL INTERVENTION
MICROVASCULAR COMPLICATIONS
ECONOMIC-EVALUATION
NEPHROPATHY
CAPTOPRIL
RAMIPRIL
MICROALBUMINURIA
PROGRESSION
EFFICACY

Access to Document

10.2337/diacare.27.8.1897

Handle.net

Persistent link

Cite this

Palmer, A. J., Annemans, L., Roze, S., Lamotte, M., Lapuerta, P., Chen, R., Gabriel, S., Carita, P., Rodby, R. A., Parving, H. H., & de Zeeuw, D. (2004). Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care, 27(8), 1897 - 1903. https://doi.org/10.2337/diacare.27.8.1897

Palmer, A.J. ; Annemans, L. ; Roze, S. et al. / Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. In: Diabetes Care. 2004 ; Vol. 27, No. 8. pp. 1897 - 1903.

@article{eb0f630a06c6405785ac9ae313be637e,

title = "Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease",

keywords = "URINARY ALBUMIN EXCRETION, MULTIFACTORIAL INTERVENTION, MICROVASCULAR COMPLICATIONS, ECONOMIC-EVALUATION, NEPHROPATHY, CAPTOPRIL, RAMIPRIL, MICROALBUMINURIA, PROGRESSION, EFFICACY",

author = "A.J. Palmer and L. Annemans and S. Roze and M. Lamotte and P. Lapuerta and R. Chen and S. Gabriel and P. Carita and R.A. Rodby and H.H. Parving and \{de Zeeuw\}, Dick",

note = "Article",

year = "2004",

doi = "10.2337/diacare.27.8.1897",

language = "Dutch",

volume = "27",

pages = "1897 -- 1903",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "AMER DIABETES ASSOC",

number = "8",

}

Palmer, AJ, Annemans, L, Roze, S, Lamotte, M, Lapuerta, P, Chen, R, Gabriel, S, Carita, P, Rodby, RA, Parving, HH & de Zeeuw, D 2004, 'Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease', Diabetes Care, vol. 27, no. 8, pp. 1897 - 1903. https://doi.org/10.2337/diacare.27.8.1897

Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. / Palmer, A.J.; Annemans, L.; Roze, S. et al.
In: Diabetes Care, Vol. 27, No. 8, 2004, p. 1897 - 1903.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease

AU - Palmer, A.J.

AU - Annemans, L.

AU - Roze, S.

AU - Lamotte, M.

AU - Lapuerta, P.

AU - Chen, R.

AU - Gabriel, S.

AU - Carita, P.

AU - Rodby, R.A.

AU - Parving, H.H.

AU - de Zeeuw, Dick

N1 - Article

PY - 2004

Y1 - 2004

KW - URINARY ALBUMIN EXCRETION

KW - MULTIFACTORIAL INTERVENTION

KW - MICROVASCULAR COMPLICATIONS

KW - ECONOMIC-EVALUATION

KW - NEPHROPATHY

KW - CAPTOPRIL

KW - RAMIPRIL

KW - MICROALBUMINURIA

KW - PROGRESSION

KW - EFFICACY

U2 - 10.2337/diacare.27.8.1897

DO - 10.2337/diacare.27.8.1897

M3 - Article

SN - 0149-5992

VL - 27

SP - 1897

EP - 1903

JO - Diabetes Care

JF - Diabetes Care

IS - 8

ER -

Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care. 2004;27(8):1897 - 1903. doi: 10.2337/diacare.27.8.1897